EyeTechCare has received CE mark extension for new indications for a focused ultrasound treatment to reduce IOP in glaucoma patients, according to a press release.
The treatment will now have a broader application for all patients with uncontrolled glaucoma, regardless of previous treatment, the release said.
“From now on, the treatment can be offered to a far greater number of patients. We are convinced that this new therapeutic procedure will soon play a key role in the management of glaucoma patients who are often apprehensive about having surgery,” Dietrich Wolf, CEO of EyeTechCare, said in the release.
Clinical trials for the EyeOP1 started in 2010, with the pilot, EyeMUST 1 and EyeMUST 2 studies having positive tolerance and efficacy results. In EyeMUST 3, 30 patients with uncontrolled glaucoma under hypotensive medical treatment showed successful results after 12 months, the release said.